Combination Of The Application Of Antibodies For Immunostimulation Together With Glucocorticoids

Abstract

The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid.

1 . A method for reducing the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. 
     
     
         2 . The method of  claim 1 , wherein the glucocorticoid is a synthetic glucocorticoid. 
     
     
         3 . The method of  claim 2 , wherein the synthetic glucocorticoid is selected from the group consisting of prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, dexamethasone, cortisone acetate, prednylidene, deflazacort, cloprednol, fluocortolone and budenoside. 
     
     
         4 . The method of  claim 1 , wherein the disease is a cancerous disease. 
     
     
         5 . The method of  claim 5 , wherein the cancerous disease is selected from the group consisting of gastric carcinoma, adenocarcinoma, malignant melanoma, colonic carcinoma, pancreatic carcinoma, ovarian carcinoma, uterine carcinoma, hepatocellular carcinoma, all histological types of bronchial carcinoma, lymphomas, sarcomas, blastomas and gastrointestinal stromal tumour (GIST). 
     
     
         6 . The method of  claim 1 , wherein the antibody is a monoclonal antibody, a chimeric antibody, humanised antibody, human antibody, trifunctional antibody, multispecific antibody and/or multifunctional antibody. 
     
     
         7 . The method of  claim 6 , wherein the multispecific antibody is a bispecific antibody which specifically recognizes a tumour antigen and a CD marker. 
     
     
         8 . The method of  claim 7 , wherein the CD marker is selected from the group consisting of CD2, CD3, CD4, CDS, CD6, CD8, CD28, and CD44. 
     
     
         9 . The method of  claim 7 , wherein the tumour antigen is selected from the group consisting of EpCAM, HER2/neu, HER3/neu, G250, CEA, MAGE, VEGF, GD3, EGFR, aVj33-integrin, HLA, HLA-DR, ASC, CD1, CD7, CD11, CD13, CD14, CD19, CD20, CD21, CD22, CD23, CD24, CD33, CD40, CD41, CD52, c-erb-2, CALLA, MHCII, CD44v3, CD44v6, CD117, p97, ganglioside GD2, GD3, C215, antigen of the antibody 9.2.27, antigen of the antibody NE150 and antigen of the antibody CA125. 
     
     
         10 . The method of  claim 6 , wherein the antibody is trifunctional with the specificity anti-EpCAM x anti-CD3 or anti-HER2/neu x anti-CD3. 
     
     
         11 . The method of  claim 1 , wherein the antibody and/or the glucocorticoid is/are administered intraperitoneally, intravenously, intra-arterially, intramuscularly, intradermally, subcutaneously, intratumourally or selectively into a defined organ. 
     
     
         12 . The method of  claim 11 , wherein the selective administration into a defined organ is undertaken via a catheter into the supplying vessel. 
     
     
         13 . The method of  claim 12 , wherein the defined organ is a liver and administration into the liver is undertaken via a catheter into the A. hepatica. 
     
     
         14 . The method of  claim 1 , wherein the glucocorticoid and the antibody are administered simultaneously. 
     
     
         15 . Pharmaceutical composition containing at least one immunostimulating antibody and at least one glucocorticoid, optionally in conjunction with one or more pharmaceutically compatible carriers and/or adjuvant substances. 
     
     
         16 . Pharmaceutical composition according to  claim 15 , wherein the glucocorticoid is a synthetic glucocorticoid. 
     
     
         17 . Pharmaceutical composition according to  claim 15 , wherein the glucocorticoid is selected from the group consisting of prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, dexamethasone, cortisone acetate, prednylidene, deflazacort, cloprednol, fluocortolone and budenoside. 
     
     
         18 . Pharmaceutical composition of  claim 15 , wherein the antibody is a monoclonal antibody, chimeric antibody, humanised antibody, human antibody, trifunctional antibody, multispecific antibody and/or multifunctional antibody. 
     
     
         19 . Pharmaceutical composition of  claim 15 , wherein the antibody is specific against a tumour antigen or a CD marker. 
     
     
         20 . Pharmaceutical composition of  claim 19 , wherein the CD marker is selected from the group consisting of CD2, CD3, CD4, CDS, CD6, CD8, CD28 and CD44.